糖皮质激素受体与PPARγ共激活可预防小鼠特应性进程恶化
该研究在小鼠特应性进程模型中,经皮肤反复暴露屋尘螨后再经肺暴露屋尘螨,并局部给予糖皮质激素受体/过氧化物酶体增殖物激活受体γ激动剂。皮肤联合激活较单药激活更明显减轻皮肤炎症,但不足以避免肺部过敏免疫反应,却通过抑制Th17反应有效降低哮喘严重度。
要点
- 皮肤联合激活糖皮质激素受体/PPARγ较单药更明显减轻屋尘螨诱导的皮肤炎症。
- 皮肤炎症减轻不足以避免肺部过敏免疫反应,但可降低哮喘严重度。
- 联合激活通过抑制Th17反应减轻哮喘严重度,树突状细胞中附加抗炎作用更明显。
核心结论
- 糖皮质激素受体/PPARγ共激活是抗过敏性皮肤炎症及预防特应性进程恶化的有效手段。
研究设计与样本
- 研究采用小鼠特应性进程模型,经皮肤反复暴露屋尘螨后再经肺暴露屋尘螨。
- 为消除特应性皮炎,小鼠接受糖皮质激素受体/PPARγ激动剂局部治疗。
- 在原代角质形成细胞和树突状细胞上评估核受体配体效应。
主要发现
- 既往屋尘螨诱导的皮肤炎症加重过敏性气道炎症,并诱导肺部混合Th2/Th17反应。
- 皮肤联合激活糖皮质激素受体/PPARγ较单药激活更明显减轻皮肤炎症。
- 附加抗炎效应在树突状细胞中较角质形成细胞更明显。
- 皮肤炎症减轻不足以避免肺部过敏免疫反应,但通过抑制Th17反应有效降低哮喘严重度。
临床怎么用
- 局部联合激活糖皮质激素受体/PPARγ可用于减轻过敏性皮肤炎症。
- 该策略可能通过抑制Th17反应降低特应性进程中的哮喘严重度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with atopic dermatitis show an increased risk to develop asthma later in life, a phenomenon referred to as "atopic march," which emphasizes the need for secondary prevention therapies. This study aimed to investigate whether relief of skin inflammation by glucocorticoids and peroxisome proliferator-activated receptor agonists might influence the subsequent development of asthma in a murine model for the atopic march in which mice were repeatedly exposed to house dust mite via the skin, followed by exposure to house dust mite in lungs. To abrogate atopic dermatitis, mice received topical treatment with glucocorticoid receptor/peroxisome proliferator-activated receptor-γ agonists. Nuclear receptor ligand effects were assessed on primary keratinocytes and dendritic cells, as central players in skin inflammation. Prior house dust mite-induced skin inflammation aggravates allergic airway inflammation and induces a mixed T helper type 2/T helper type 17 response in the lungs. Cutaneous combined activation of glucocorticoid receptor/peroxisome proliferator-activated receptor-γ reduced skin inflammation to a higher extent compared to single activation. Additive anti-inflammatory effects were more prominent in dendritic cells, as compared to keratinocytes. Alleviation of allergic skin inflammation by activation of glucocorticoid receptor/peroxisome proliferator-activated receptor-γ appeared insufficient to avoid the allergic immune response in the lungs, but efficiently reduced asthma severity by counteracting the Th17 response. Glucocorticoid receptor/peroxisome proliferator-activated receptor-γ co-activation represents a potent remedy against allergic skin inflammation and worsening of atopic march.
引用
- Deckers J, Bougarne N, Mylka V, et al. Co-Activation of Glucocorticoid Receptor and Peroxisome Proliferator-Activated Receptor-γ in Murine Skin Prevents Worsening of Atopic March. J Invest Dermatol. 2017. PMID: 29288652. doi:10.1016/j.jid.2017.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。